Koers Exicure Inc Other OTC
Aandelen
US30205M1018
Biotechnologie & Medisch Onderzoek
Omzet 2021 | -483K -449K | Omzet 2022 | 28,83 mln. 26,79 mln. | Marktkapitalisatie | 5,71 mln. 5,31 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -64 mln. -59,47 mln. | Nettowinst (verlies) 2022 | -2 mln. -1,86 mln. | EV/omzet 2021 | 8,21 x |
Nettoliquiditeiten 2021 | 24,4 mln. 22,68 mln. | Nettoliquiditeiten 2022 | 1,27 mln. 1,18 mln. | EV/omzet 2022 | 0,15 x |
K/w-verhouding 2021 |
-0,28
x | K/w-verhouding 2022 |
-2,06
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 54,96% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 24-02-23 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01-12-22 |
Investor Relations Contact | 47 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01-12-22 |
Paul Kang
CEO | Chief Executive Officer | 63 | 24-02-23 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 23-08-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |